Pilot Projects Program

太平洋创新、知识和机遇中心(PIKO)的首要目标是 为临床和转化性研究(CTR)开发强大的基础设施，旨在缓解健康问题 土著太平洋人(IPP)的差异，定义为夏威夷土著人、其他太平洋岛民和 菲律宾人以及其他未得到充分服务的人群(如移民、无家可归者、性和性别 少数族裔)。为了实现这一目标，将设计一个试点项目方案(PPP)，以提供资金， 在竞争的基础上，提供给初级调查员(JI)和资深调查员(EI)，他们正在寻求 他们的研究计划发生了重大变化。他们将来自夏威夷大学的教职员工， 夏威夷太平洋大学和火奴鲁鲁夏米纳德大学。资金将优先用于创新、 高质量、有影响力的T1-T5 CTR试点项目，重点是T3-T5，可加速翻译 临床和生物医学研究，以改善IPP和其他疾病的患者护理和改善公共健康 服务不足的人群。为试点项目提供支持预计将导致更多的研究 提高联合执行/综合执行的主流外部资金的生产率和竞争力。此外，鉴于严重的 对NIH资助的科学劳动力老龄化和IPP主要研究人员缺乏的担忧， 我们将积极鼓励IPP JI/EI的申请。因此，购买力平价核心目标将通过以下途径实现 以下是具体目标： 具体目标1：通过制定资格标准征集、审查和资助有价值的试点项目，以及 管理招标程序和申请提交程序；并通过建立审查标准和 管理评审、资金决定和奖励审批流程。 具体目标2：通过监测和评价试点项目，提供授标后监督和评价 评估获奖者的表现、进展、生产率和投资回报；并通过确保 获奖者遵守进行CTR的联邦政策、规则和指导方针。 到五年结束时，PIKO PPP核心将资助35至45个JI/EI，以进行文化响应 科学严谨的CTR试点项目侧重于改善IPP和其他医学方面的健康状况 服务不足和弱势群体。这些试点项目的初步数据将用于确保 联邦和国家拨款。联检组/审评组的大部分资金将来自IPP背景，从而增加 IPP调查人员成功竞争NIH或其他外部资金的数量。

The overarching goal of the Center for Pacific Innovations, Knowledge, and Opportunities (PIKO) is to develop a robust infrastructure for clinical and translational research (CTR), intending to mitigate health disparities in Indigenous Pacific People (IPP), defined as Native Hawaiians, Other Pacific Islanders, and Filipinos, as well as in other underserved populations (e.g., immigrants, homeless, and sexual and gender minorities). To achieve this goal, a Pilot Project Program (PPP) will be designed to provide funding, on a competitive basis, to Junior Investigators (JI) and Established Investigators (EI) who are seeking to make significant changes to their research program. They will come from the faculty of the University of Hawaii, Hawaii Pacific University, and Chaminade University of Honolulu. Funding will be prioritized toward innovative, high quality, and impactful T1–T5 CTR pilot projects, with an emphasis on T3-T5, that accelerate the translation of clinical and biomedical research into better patient care and improved public health for IPP and other underserved populations. The provision of support for pilot projects is expected to result in heightened research productivity and increased competitiveness for mainstream extramural funding for JI/EI. Also, given the serious concerns about the aging of the NIH-funded scientific workforce, and the dearth of IPP principal investigators, we will actively encourage applications from IPP JI/EI. Thus, the PPP Core objective will be achieved through the following Specific Aims: Specific Aim 1: Solicit, review, and fund meritorious pilot projects by developing eligibility criteria, and managing solicitation procedures and application submission processes; and by establishing review criteria and managing review, funding-decision, and award-approval processes. Specific Aim 2: Provide post-award oversight and evaluation of pilot projects by monitoring and evaluating the performance, progress, productivity, and return on investment of the awardees; and by assuring awardees comply with federal policies, rules, and guidelines for conducting CTR. By the end of five years, the PIKO PPP Core will have funded 35 to 45 JI/EI to conduct culturally responsive and scientifically rigorous CTR pilot projects focused on improving the health of IPP and other medically underserved and vulnerable populations. Preliminary data from these pilot projects will be used to secure federal and national grant funding. Most of the funded JI/EI will be from IPP backgrounds, thereby increasing the number of IPP investigators successfully competing for NIH or other extramural funding.